Detection method of melogabalin besylate
By derivatizing melogabarin p-benzenesulfonate and combined with liquid chromatography, the problem of difficult detection of specific impurities during the synthesis process is solved, accurate detection and separation of impurities is achieved, and effective quality control means are provided.
Patent Information
- Application Number
- CN202410933538.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-01
AI Technical Summary
The specific impurities produced during the synthesis of melogabarin benzenesulfonate are difficult to effectively detect and control quality due to their similar structure to the target and lack of ultraviolet detection chromogenic groups.
Benzyloxycarbonylsuccinimide as derivatization reagent, melogabarin benzenesulfonate was derivatized, and benzyloxycarbonyl with strong UV absorption was introduced, and gradient elution and analysis were carried out by liquid chromatography. , realize the detection and separation of specific impurities.
This method can accurately detect specific impurities, realize the effective separation of the main peak and the impurity peak, and provides a new quality control method to ensure the product purity of melogabarin benzenesulfonate.
Smart Images

Figure BDA0004940568420000011 
Figure BDA0004940568420000012 
Figure BDA0004940568420000021
Abstract
Description
Technical Field
[0001] The invention relates to a method for detecting melogabalin besylate, and in particular to a method for detecting specific impurities in melogabalin besylate. Background Art
[0002] Mirogabalin Besylate (Molecular formula: C 18 H 25 NO 5 S, chemical name: 2-((1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl)acetate benzenesulfonate) is a GABA analog developed by Daiichi Sankyo Co., Ltd. of Japan. It can act on the α2-δ1 subunit of the voltage-sensitive calcium channel complex (widely present in the nervous system that mediates pain transmission and processing throughout the body), thereby playing a role in treating chronic neuropathic pain.
[0003]
[0004] The following impurities are produced during the synthesis of melogabalin besylate. Since the impurities have a similar structure to melogabalin besylate and lack a chromophore that can be used for UV detection, there is no detection method for the above impurities and there is a lack of effective quality control strategies.
[0005] Summary of the invention
[0006] Purpose of the invention: The present invention aims to provide a detection method for specific impurities in melogabalin besylate for effective elution, separation and quantitative analysis.
[0007] Technical solution: The detection method of melogabalin besylate described in the present invention comprises the following steps:
[0008] (1) Derivatization treatment: using benzyloxycarbonyl succinimide as a derivatization reagent to prepare the test sample;
[0009] (2) Detection: liquid chromatography was performed using a pentafluorophenyl bonded silica gel column, 0.1% acidic buffer solution as mobile phase A, and an organic solvent as mobile phase B, with gradient elution;
[0010] (3) Analysis results: Calculate the content of each target component.
[0011] Wherein, the structure of the detection target component is as follows:
[0012]
[0013] Preferably, the derivatization method in step (1) is to react melogabalin besylate with benzyloxycarbonyl succinimide at 25-60°C for 5-60 minutes in a water-tetrahydrofuran mixed solution containing an alkaline reagent; the reaction temperature is specifically selected from 25°C, 30°C, 35°C, 40°C, 50°C, 60°C, and the reaction time is specifically selected from 5 minutes, 10 minutes, 15 minutes, 30 minutes, 40 minutes, 50 minutes, 60 minutes.
[0014] Further preferably, the derivatization method is to react melogabalin benzenesulfonate with benzyloxycarbonyl succinimide at 25-40°C for 5-30 minutes in a water-tetrahydrofuran mixed solution containing an alkaline reagent; the reaction temperature is specifically selected from 25°C, 30°C, 35°C, and 40°C, and the reaction time is specifically selected from 5 minutes, 10 minutes, 15 minutes, and 30 minutes.
[0015] More preferably, the derivatization method is to react melogabalin benzenesulfonate with benzyloxycarbonyl succinimide at 25-30°C for 5 minutes in a water-tetrahydrofuran mixed solution containing an alkaline reagent; the reaction temperature is specifically selected from 25°C and 30°C.
[0016] Still more preferably, the derivatization treatment method is to react melogabalin benzenesulfonate with benzyloxycarbonyl succinimide at 25° C. for 5 minutes in a water-tetrahydrofuran mixed solution containing an alkaline reagent.
[0017] More preferably, the alkaline reagent is sodium carbonate, and the volume ratio of water to tetrahydrofuran in the mixed solution is 70:30.
[0018] More preferably, the molar ratio of melogabalin besylate, benzyloxycarbonyl succinimide and alkaline agent is 1:(1.0-2.0):(2.0-4.0).
[0019] More preferably, the molar ratio of melogabalin besylate, benzyloxycarbonyl succinimide and alkaline agent is selected from 1:1.2:2.4, 1:1.5:2.4, 1:1.5:4.0 and 1:2.0:4.0.
[0020] Still more preferably, the molar ratio of melogabalin besylate, benzyloxycarbonyl succinimide and alkaline reagent is 1:1.2:2.4.
[0021] Still further preferably, the derivatization treatment method is to react melogabalin benzylsulfonate with benzyloxycarbonyl succinimide at 25°C for 5 minutes in a water-tetrahydrofuran (70:30, V / V) mixed solution containing sodium carbonate, according to the molar ratio of melogabalin benzylsulfonate: benzyloxycarbonyl succinimide: sodium carbonate = 1:1.2:2.4.
[0022] Preferably, the concentration of the sample in step (1) is 1 mg / ml.
[0023] Preferably, in terms of volume fraction of mobile phase A, the elution procedure of the gradient elution in step (2) includes: 0-30 minutes, 67%-73%→22%-28%; 30-35 minutes, 22%-28%→2%-8%; 35-40 minutes, 2%-8%.
[0024] Further preferably, the elution procedure is as follows:
[0025]
[0026] Preferably, in step (2), mobile phase A is 0.1V% perchloric acid solution, and mobile phase B is acetonitrile.
[0027] Preferably, the chromatographic column in step (2) has a length of 100 to 250 mm, a diameter of 4.6 mm, and a filler particle size of 3 to 5 μm.
[0028] More preferably, the chromatographic column has a length of 150 mm, a diameter of 4.6 mm, and a filler particle size of 5 μm.
[0029] More preferably, the chromatographic column is Phenomenex Kinetex PFP4.6×150mm, 5μm.
[0030] Preferably, the detection wavelength of the detection in step (2) is 200-220 nm, the column temperature of the chromatographic column is 27-33° C., and the flow rate of the mobile phase is 0.9-1.1 ml / min.
[0031] More preferably, the detection wavelength is 210 nm, the column temperature of the chromatographic column is 30° C., and the flow rate of the mobile phase is 1.0 ml / min.
[0032] Preferably, the injection volume for detection in step (3) is 5 μl.
[0033] Preferably, step (3) uses area normalization method to calculate the content of each detection target component.
[0034] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages:
[0035] The derivatization detection method of melogabalin benzylsulfonate designed by the present invention is to carry out derivatization treatment on melogabalin benzylsulfonate and its specific impurities by using benzyloxycarbonyl succinimide, introduce benzyloxycarbonyl with strong ultraviolet absorption, generate a derivatization product with absorption in the ultraviolet region of 195 to 215 nm, and detect it by using HPLC-DAD detector. The method can accurately detect specific impurities and realize effective separation of main peak and specific impurity peak, and is a new and effective quality control method of melogabalin benzylsulfonate. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 The effect of different derivatization reagents on the derivatization treatment;
[0037] Figure 2 The effects of different derivatization conditions on the derivatization treatment are as follows: (a) the effect of water content in the reaction system on the derivatization treatment; (b) the effect of reaction temperature on the derivatization treatment; (c) the effect of reaction time on the derivatization treatment; (d) the effect of the molar ratio of melogabalin benzenesulfonate sample, benzyloxycarbonyl succinimide and alkaline reagent on the derivatization treatment;
[0038] Figure 3 It is the detection chromatogram of the blank solution under the optimal derivatization conditions;
[0039] Figure 4 The figure is the detection chromatogram of the system suitability solution under the optimal derivatization conditions. DETAILED DESCRIPTION
[0040] The technical solution of the present invention is further described below in conjunction with embodiments.
[0041] Example 1: Screening of derivatization reagents
[0042] 1. Experimental methods
[0043] The peak area of melogabalin benzenesulfonate derivatives was used as an indicator to study the effect of different derivatization reagents on the derivatization efficiency. The derivatization reagents used were benzoyloxycarbonyl succinimide (Cbz-osu), benzyl chloroformate (Cbz-Cl), p-toluenesulfonyl chloride (Tos-Cl), o-nitrobenzenesulfonyl chloride (NBSC), fluorenylmethoxycarbonyl chloride (Fmoc-Cl) and di-tert-butyl dicarbonate (Boc).
[0044] Derivatization conditions: The molar ratio of sample, derivatization reagent and sodium carbonate is 1:1.2:2.4, the reaction is carried out in water-tetrahydrofuran (70:30), the reaction is carried out at 25-30°C for 5 minutes, and the sample is injected into HPLC-DAD for analysis. The sample concentration is 1 mg / ml.
[0045] HPLC-DAD conditions:
[0046] Instrument model: Thermo Scientific UltiMate 3000 liquid chromatography system;
[0047] Column: Phenomenex Kinetex PFP 4.6×150 mm, 5 μm;
[0048] Mobile phase: Phase A: 0.1% perchloric acid solution, Phase B: acetonitrile;
[0049] Detection wavelength: 210nm;
[0050] Flow rate: 1.0ml / min;
[0051] Column temperature: 30°C;
[0052] Injection volume: 5 μl;
[0053] The gradient elution program is shown in Table 1.
[0054] Table 1. Gradient elution program for Example 1
[0055] Elution time (min) Phase A (%) Phase B (%) 0 70 30 30 25 75 35 5 95 40 5 95 40.1 70 30 45 70 30
[0056] 2. Experimental results
[0057] Depend on Figure 1 It can be seen that when Cbz-Osu is used as the derivatization reagent, the peak area of the derivatization product is the largest. Therefore, Cbz-Osu is used as the derivatization reagent.
[0058] Example 2: Screening of derivatization conditions
[0059] 1. Experimental methods
[0060] Taking the peak area of melogabalin besylate derivatives as an indicator, a single factor experiment was conducted to study the effects of water content of the reaction system (50%, 60%, 65%, 70%, 75%, 80%, 90%, v / v), reaction temperature (25℃, 30℃, 35℃, 40℃, 50℃, 60℃), reaction time (5min, 10min, 15min, 30min, 40min, 50min, 60min), and the molar ratio of melogabalin besylate, benzyloxycarbonyl succinimide and sodium carbonate (1:1.0:2.0, 1:1.1:2.2, 1:1.2:2.4, 1:1.5:2.4, 1:1.5:4.0, 1:2.0:4.0) on the derivatization efficiency.
[0061] In the experiment, the concentration of melogabalin besylate in the system was 1 mg / mL; the HPLC-DAD conditions were consistent with those in Example 1.
[0062] 2. Experimental results
[0063] Since sodium carbonate is soluble in water and Cbz-Osu is soluble in tetrahydrofuran, the ratio of water to tetrahydrofuran in the reaction system needs to be further screened. Figure 2 (a) It can be seen that when water-tetrahydrofuran (70:30, v / v) is used in the reaction system, the peak area of the derivative product is the largest. Therefore, water-tetrahydrofuran (70:30, v / v) is finally selected as the solvent.
[0064] Depend on Figure 2 (b) It can be seen that when the derivatization reaction temperature is 25°C, 30°C, 35°C, 40°C, 50°C, and 60°C, the peak area of the derivatization product does not change significantly. This indicates that the reaction temperature has little effect on the derivatization reaction rate, and the derivatization reaction can proceed rapidly at 25-30°C.
[0065] Depend on Figure 2 (c) It can be seen that when the derivatization reaction time is 5min, 10min, 15min, 30min, 40min, 50min, and 60min, the peak area of the derivatization product has no obvious change, and the final reaction time is selected as 5min.
[0066] Depend on Figure 2 (d) It can be seen that when the molar ratio of melogabalin besylate sample, Cbz-Osu and sodium carbonate is 1:1.2:2.4, 1:1.5:2.4, 1:1.5:4.0, 1:2.0:4.0, the peak area of the derivatized product has no obvious change. Therefore, the molar ratio of melogabalin besylate sample, Cbz-Osu and sodium carbonate is finally selected to be 1:1.2:2.4.
[0067] In summary, the optimal derivatization conditions were finally selected: the reaction system was water-tetrahydrofuran (70:30, v / v), the derivatization reagent was benzyloxycarbonyl succinimide, the molar ratio of melogabalin benzenesulfonate sample, benzyloxycarbonyl succinimide and sodium carbonate was 1:1.2:2.4, and the reaction was carried out at 25°C for 5 min. The HPLC-DAD conditions were the same as those in Example 1.
[0068] Example 3: Methodological Validation
[0069] 1. Experimental methods
[0070] Methodological validation was performed under the above-mentioned optimal derivatization conditions. The chromatographic conditions were consistent with those in Example 1. The remaining methods were based on the "Technical Guidelines for Validation of Analytical Methods for Quality Control of Chemical Drugs" issued by the Drug Review Center of the State Food and Drug Administration and the "Guidelines for Validation of Analytical Methods for Drug Quality Standards" of the Chinese Pharmacopoeia.
[0071] 2. Experimental results
[0072] The results of the methodological validation are shown in Table 2.
[0073] Table 2. Verification results and conclusions
[0074]
[0075] It can be seen from the above methodological verification results that the detection method designed by the present invention has strong specificity, wide linear range, high sensitivity, high accuracy, good stability and durability, and can achieve effective detection of melogabalin besylate and its specific impurities.
Claims
1. A method for detecting melogabalin besylate, characterized in that: The following steps are involved: (1) Derivatization treatment: using benzyloxycarbonyl succinimide as a derivatization reagent to prepare the test sample; (2) Detection: liquid chromatography was performed using a pentafluorophenyl bonded silica gel column, 0.1% acidic buffer solution as mobile phase A, and an organic solvent as mobile phase B, with gradient elution; (3) Analysis results: Calculate the content of each target component.
2. The detection method according to claim 1, characterized in that The structure of the detection target component is as follows:
3. The detection method according to claim 1, characterized in that: The derivatization method in step (1) is to react melogabalin benzenesulfonate with benzyloxycarbonyl succinimide at 25-60° C. for 5-60 minutes in a water-tetrahydrofuran mixed solution containing an alkaline reagent.
4. The detection method according to claim 3, characterized in that: The alkaline reagent is sodium carbonate, and the volume ratio of water to tetrahydrofuran in the mixed solution is 70:
30.
5. The detection method according to claim 3, characterized in that: The molar ratio of melogabalin besylate, benzyloxycarbonyl succinimide and alkaline reagent is 1:(1.0-2.0):(2.0-4.0).
6. The detection method according to claim 1, characterized in that: According to the volume fraction of mobile phase A, the elution procedure of the gradient elution in step (2) includes: 0-30 minutes, 67%-73%→22%-28%; 30-35 minutes, 22%-28%→2%-8%; 35-40 minutes, 2%-8%.
7. The detection method according to claim 6, characterized in that: The elution procedure is as follows:
8. The detection method according to claim 1, characterized in that: In step (2), mobile phase A is 0.1V% perchloric acid solution, and mobile phase B is acetonitrile.
9. The detection method according to claim 1, characterized in that: The column length of the chromatographic column in step (2) is 100-250 mm, the diameter is 4.6 mm, and the filler particle size is 3-5 μm.
10. The detection method according to claim 1, characterized in that: The detection wavelength of the detection in step (2) is 200-220 nm, the column temperature of the chromatographic column is 27-33° C., and the flow rate of the mobile phase is 0.9-1.1 ml / min.
Citation Information
Cited By
Preparation method of melogabalin besylate key intermediate
CN119684106A
Method for analyzing impurity spectrum of melogabalin besylate bulk drug
CN119688890A
